Immunotherapy combo tested against untreatable liver cancer
NCT ID NCT07679061
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its safety and effectiveness in real-world practice. The main focus is on tracking immune-related liver side effects and how well the drugs control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab plus ipilimumab
What this could lead to
If successful, this could confirm that combining these two immunotherapy drugs is a safe and effective standard treatment for advanced liver cancer that cannot be surgically removed.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The combination can cause immune-related side effects, including liver injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Mebix. Inc
RECRUITINGMinato-ku, Tokyo, 1050001, Japan
Contact
-
National Cancer Center Hospital East
RECRUITINGChiba, Japan